Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases - PubMed (original) (raw)

Review

Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases

R N Brogden et al. Drugs. 1982 Oct.

Abstract

Ranitidine is a new histamine H2-receptor antagonist which, unlike cimetidine, does not contain an imidazole group. On a weight basis, ranitidine is 4 to 10 times more potent than cimetidine in inhibiting stimulated gastric acid secretion in humans. Therapeutic trials comparing ranitidine and cimetidine have demonstrated that ranitidine 150 mg twice daily is an effective alternative to cimetidine 1000 mg daily in 4 divided doses in increasing the rate of healing of duodenal and gastric ulcers over a period of 4 to 6 weeks. Ranitidine, given as a single 150 mg dose at night, decreases the incidence of ulcer recurrence. Preliminary studies in the Zollinger-Ellison syndrome and in patients intolerant of, or unresponsive to cimetidine, indicate that ranitidine controls the gastric hyperacidity and heals most ulcers, including those which failed to respond to months of treatment with cimetidine 1 to 1.6 g daily. Ranitidine, unlike cimetidine, has no antiandrogenic effects and does not alter hepatic metabolism of drugs. Ranitidine is well tolerated. Preliminary reports of the resolution of cimetidine-induced adverse effects following substitution of ranitidine, suggest that ranitidine may be of value in patients intolerant of cimetidine. However, wider clinical experience with ranitidine is needed to determine the clinical relevance of these reports.

PubMed Disclaimer

Cited by

FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years.
Bindra S, Bose K, Thekkantavida AC, Grace Thomas Parambi D, Alsahli TG, Pant M, Pappachen LK, Kim H, Mathew B. Bindra S, et al. RSC Adv. 2024 Sep 2;14(38):27657-27696. doi: 10.1039/d4ra04730c. eCollection 2024 Aug 29. RSC Adv. 2024. PMID: 39224646 Free PMC article. Review.
Role of Marine Bacterial Contaminants in Histamine Formation in Seafood Products: A Review.
Oktariani AF, Ramona Y, Sudaryatma PE, Dewi IAMM, Shetty K. Oktariani AF, et al. Microorganisms. 2022 Jun 11;10(6):1197. doi: 10.3390/microorganisms10061197. Microorganisms. 2022. PMID: 35744715 Free PMC article. Review.
Multicomponent double Mannich alkylamination involving C(sp2)-H and benzylic C(sp3)-H bonds.
Lai Z, Wu R, Li J, Chen X, Zeng L, Wang X, Guo J, Zhao Z, Sajiki H, Cui S. Lai Z, et al. Nat Commun. 2022 Jan 21;13(1):435. doi: 10.1038/s41467-022-28088-z. Nat Commun. 2022. PMID: 35064111 Free PMC article.
Molecular Regulation of Histamine Synthesis.
Huang H, Li Y, Liang J, Finkelman FD. Huang H, et al. Front Immunol. 2018 Jun 20;9:1392. doi: 10.3389/fimmu.2018.01392. eCollection 2018. Front Immunol. 2018. PMID: 29973935 Free PMC article. Review.
Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.
Klotz U, Reimann IW. Klotz U, et al. Pharm Res. 1984 Mar;1(2):59-62. doi: 10.1023/A:1016347229923. Pharm Res. 1984. PMID: 24277213

References

1. Lancet. 1982 Jan 23;1(8265):224 - PubMed
1. Br J Pharmacol. 1979 Jul;66(3):464P - PubMed
1. N Engl J Med. 1980 May 1;302(18):1012-4 - PubMed
1. Br Med J (Clin Res Ed). 1981 Sep 12;283(6293):699 - PubMed
1. J Pharm Sci. 1980 Oct;69(10):1155-7 - PubMed

Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases - PubMed (original) (raw)